SA521422733B1 - مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـ - Google Patents
مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـInfo
- Publication number
- SA521422733B1 SA521422733B1 SA521422733A SA521422733A SA521422733B1 SA 521422733 B1 SA521422733 B1 SA 521422733B1 SA 521422733 A SA521422733 A SA 521422733A SA 521422733 A SA521422733 A SA 521422733A SA 521422733 B1 SA521422733 B1 SA 521422733B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- kcnq
- trifluoroethoxy
- hardeners
- pyridin
- urea
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 239000004848 polyfunctional curative Substances 0.000 title 1
- 206010001497 Agitation Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000002161 motor neuron Anatomy 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 abstract 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 201000002241 progressive bulbar palsy Diseases 0.000 abstract 1
- 201000008752 progressive muscular atrophy Diseases 0.000 abstract 1
- 201000000196 pseudobulbar palsy Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521422733B1 true SA521422733B1 (ar) | 2024-02-08 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521422733A SA521422733B1 (ar) | 2019-02-06 | 2021-08-05 | مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـ |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US11208383B2 (https=) |
| EP (1) | EP3921030B1 (https=) |
| JP (2) | JP7451543B2 (https=) |
| KR (1) | KR102924196B1 (https=) |
| CN (1) | CN113692304B (https=) |
| AU (1) | AU2020218180B2 (https=) |
| BR (1) | BR112021015544A2 (https=) |
| DK (1) | DK3921030T3 (https=) |
| ES (1) | ES2968807T3 (https=) |
| FI (1) | FI3921030T3 (https=) |
| HR (1) | HRP20240012T1 (https=) |
| HU (1) | HUE064734T2 (https=) |
| IL (1) | IL285113B2 (https=) |
| LT (1) | LT3921030T (https=) |
| MX (1) | MX2021009396A (https=) |
| PL (1) | PL3921030T3 (https=) |
| PT (1) | PT3921030T (https=) |
| RS (1) | RS65040B1 (https=) |
| SA (1) | SA521422733B1 (https=) |
| SG (1) | SG11202108599SA (https=) |
| SI (1) | SI3921030T1 (https=) |
| SM (1) | SMT202400003T1 (https=) |
| WO (1) | WO2020163268A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240012T1 (hr) * | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori |
| AU2021295422A1 (en) | 2020-06-25 | 2023-02-23 | Idorsia Pharmaceuticals Ltd | Cyclobutyl-urea derivatives |
| TW202330471A (zh) * | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 環丙醯胺衍生物 |
| EP4433472A1 (en) | 2021-11-19 | 2024-09-25 | Icagen, LLC | Pyridine compounds as kv7.2 enhancers |
| JP2024542881A (ja) * | 2021-11-19 | 2024-11-18 | アイカジェン・エルエルシー | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 |
| EP4452944A1 (en) | 2021-12-22 | 2024-10-30 | Icagen, LLC | Cyclopropyl compounds |
| JP2025506201A (ja) | 2022-02-15 | 2025-03-07 | アイカジェン・エルエルシー | 新規なビシクロペンタン誘導体 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
| IT202200024963A1 (it) | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257481A (zh) * | 1997-03-25 | 2000-06-21 | 英国阿斯特拉药品有限公司 | 新的吡啶衍生物及其含有它们的药用组合物 |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| AU2005233642A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyridines as potassium ion channel modulators |
| CN1993347A (zh) * | 2004-07-29 | 2007-07-04 | 默克公司 | 钾通道抑制剂 |
| WO2010036316A1 (en) * | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) * | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| JP6364472B2 (ja) * | 2013-03-15 | 2018-07-25 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 |
| CA2936886A1 (en) * | 2014-02-27 | 2015-08-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| TWI664166B (zh) | 2014-10-24 | 2019-07-01 | 日商小野藥品工業股份有限公司 | Ｋｃｎｑ２至５通道活化劑 |
| JP6943239B2 (ja) * | 2016-04-22 | 2021-09-29 | 小野薬品工業株式会社 | Ｋｃｎｑ２〜５チャネル活性化剤 |
| HRP20240012T1 (hr) * | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori |
-
2020
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 IL IL285113A patent/IL285113B2/en unknown
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en not_active Ceased
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 KR KR1020217028040A patent/KR102924196B1/ko active Active
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 SM SM20240003T patent/SMT202400003T1/it unknown
- 2020-02-04 CN CN202080012797.0A patent/CN113692304B/zh active Active
- 2020-02-04 AU AU2020218180A patent/AU2020218180B2/en active Active
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
-
2021
- 2021-08-05 SA SA521422733A patent/SA521422733B1/ar unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US12344584B2/en active Active
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja not_active Withdrawn
-
2025
- 2025-05-27 US US19/219,238 patent/US20250282725A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422733B1 (ar) | مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـ | |
| MXPA05012840A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades. | |
| US20050004125A1 (en) | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | |
| MX2010002538A (es) | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| WO2007104783A3 (en) | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| TW200633982A (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| NO20070484L (no) | Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer. | |
| TW200505903A (en) | CGRP receptor antagonists | |
| WO2007149395A3 (en) | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer | |
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| PT672031E (pt) | Dieteres de catecol como inibidores selectivos de pde iv | |
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| MX2010002537A (es) | 4-fenil-1h-piridin-2-onas 1,3-disubstituidas. | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| MX2025000985A (es) | Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas | |
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| SA523440367B1 (ar) | مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1 | |
| WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
| RU2722014C2 (ru) | Этинильные производные |